Clinical Profile of Patients with Primary Sjögren’s Syndrome with Non-Identified Antinuclear Autoantibodies
Abstract
1. Introduction
2. Materials and Methods
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Beydon, M.; McCoy, S.; Nguyen, Y.; Sumida, T.; Mariette, X.; Seror, R. Epidemiology of Sjogren syndrome. Nat. Rev. Rheumatol. 2023, 20, 158–169. [Google Scholar] [CrossRef] [PubMed]
- Parisis, D.; Chivasso, C.; Perret, J.; Soyfoo, M.S.; Delporte, C. Current State of Knowledge on Primary Sjogren’s Syndrome, an Autoimmune Exocrinopathy. J. Clin. Med. 2020, 9, 2299. [Google Scholar] [CrossRef]
- Vilchez-Oya, F.; Balastegui Martin, H.; Garcia-Martinez, E.; Corominas, H. Not all autoantibodies are clinically relevant. Classic and novel autoantibodies in Sjogren’s syndrome: A critical review. Front. Immunol. 2022, 13, 1003054. [Google Scholar] [CrossRef] [PubMed]
- Vitali, C.; Bombardieri, S.; Jonsson, R.; Moutsopoulos, H.M.; Alexander, E.L.; Carsons, S.E.; Daniels, T.E.; Fox, P.C.; Fox, R.I.; Kassan, S.S.; et al. Classification criteria for Sjogren’s syndrome: A revised version of the European criteria proposed by the American-European Consensus Group. Ann. Rheum. Dis. 2002, 61, 554–558. [Google Scholar] [CrossRef] [PubMed]
- Shiboski, S.C.; Shiboski, C.H.; Criswell, L.; Baer, A.; Challacombe, S.; Lanfranchi, H.; Schiodt, M.; Umehara, H.; Vivino, F.; Zhao, Y.; et al. American College of Rheumatology classification criteria for Sjogren’s syndrome: A data-driven, expert consensus approach in the Sjogren’s International Collaborative Clinical Alliance cohort. Arthritis Care Res. 2012, 64, 475–487. [Google Scholar] [CrossRef]
- Shiboski, C.H.; Shiboski, S.C.; Seror, R.; Criswell, L.A.; Labetoulle, M.; Lietman, T.M.; Rasmussen, A.; Scofield, H.; Vitali, C.; Bowman, S.J.; et al. 2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjogren’s Syndrome: A Consensus and Data-Driven Methodology Involving Three International Patient Cohorts. Arthritis Rheumatol. 2017, 69, 35–45. [Google Scholar] [CrossRef] [PubMed]
- Stergiou, I.E.; Chatzis, L.G.; Pezoulas, V.C.; Baldini, C.; Fotiadis, D.I.; Voulgarelis, M.; Tzioufas, A.G.; Goules, A.V. The clinical phenotype of primary Sjogren’s syndrome patients with lymphadenopathy. Clin. Exp. Rheumatol. 2022, 40, 2357–2362. [Google Scholar] [CrossRef] [PubMed]
- Deroo, L.; Achten, H.; De Boeck, K.; Genbrugge, E.; Bauters, W.; Roels, D.; Dochy, F.; Creytens, D.; Deprez, J.; Van den Bosch, F.; et al. The value of separate detection of anti-Ro52, anti-Ro60 and anti-SSB/La reactivities in relation to diagnosis and phenotypes in primary Sjogren’s syndrome. Clin. Exp. Rheumatol. 2022, 40, 2310–2317. [Google Scholar] [CrossRef] [PubMed]
- Lee, Y.; Jeon, H.S.; Hyon, J.Y. Correlations between clinical parameters of dry eye disease and serologic profiles in Sjogren’s syndrome. Graefes Arch. Clin. Exp. Ophthalmol. 2022, 260, 2925–2932. [Google Scholar] [CrossRef]
- Chatzis, L.G.; Pezoulas, V.; Voulgari, P.V.; Baldini, C.; Exarchos, T.P.; Fotiadis, D.I.; Mavragani, C.P.; Skopouli, F.N.; Moutsopoulos, H.M.; Tzioufas, A.G.; et al. Combined seronegativity in Sjogren’s syndrome. Clin. Exp. Rheumatol. 2021, 39 (Suppl. 133), 80–84. [Google Scholar] [CrossRef]
- Fossaluzza, V.; De Vita, S. Clinical differences between ANA/anti-ENA positive or negative primary Sjogren’s syndrome. Clin. Rheumatol. 1992, 11, 385–387. [Google Scholar] [CrossRef] [PubMed]
- Quartuccio, L.; Baldini, C.; Bartoloni, E.; Priori, R.; Carubbi, F.; Corazza, L.; Alunno, A.; Colafrancesco, S.; Luciano, N.; Giacomelli, R.; et al. Anti-SSA/SSB-negative Sjogren’s syndrome shows a lower prevalence of lymphoproliferative manifestations, and a lower risk of lymphoma evolution. Autoimmun. Rev. 2015, 14, 1019–1022. [Google Scholar] [CrossRef]
- Baldini, C.; Pepe, P.; Quartuccio, L.; Priori, R.; Bartoloni, E.; Alunno, A.; Gattamelata, A.; Maset, M.; Modesti, M.; Tavoni, A.; et al. Primary Sjogren’s syndrome as a multi-organ disease: Impact of the serological profile on the clinical presentation of the disease in a large cohort of Italian patients. Rheumatology 2014, 53, 839–844. [Google Scholar] [CrossRef] [PubMed]
- Sluijpers, N.R.F.; Delli, K.; De Wolff, L.; Stel, A.J.; Spijkervet, F.K.L.; Kroese, F.G.M.; Bootsma, H.; Arends, S.; Vissink, A. Longitudinal evaluation of major salivary gland functioning in Sjogren’s disease patients in a prospective standard-of-care cohort. Clin. Exp. Rheumatol. 2023, 41, 2474–2483. [Google Scholar] [CrossRef] [PubMed]
- Gairy, K.; Knight, C.; Anthony, P.; Hoskin, B. Burden of illness among subgroups of patients with primary Sjogren’s syndrome and systemic involvement. Rheumatology 2021, 60, 1871–1881. [Google Scholar] [CrossRef] [PubMed]
- Narvaez, J.; Sanchez-Fernandez, S.A.; Seoane-Mato, D.; Diaz-Gonzalez, F.; Bustabad, S. Prevalence of Sjogren’s syndrome in the general adult population in Spain: Estimating the proportion of undiagnosed cases. Sci. Rep. 2020, 10, 10627. [Google Scholar] [CrossRef]
- Ter Borg, E.J.; Kelder, J.C. Is extra-glandular organ damage in primary Sjogren’s syndrome related to the presence of systemic auto-antibodies and/or hypergammaglobulinemia? A long-term cohort study with 110 patients from the Netherlands. Int. J. Rheum. Dis. 2017, 20, 875–881. [Google Scholar] [CrossRef]
- Chatzis, L.; Pezoulas, V.C.; Ferro, F.; Gandolfo, S.; Donati, V.; Binutti, M.; Callegher, S.Z.; Venetsanopoulou, A.; Zampeli, E.; Mavrommati, M.; et al. Sjogren’s Syndrome: The Clinical Spectrum of Male Patients. J. Clin. Med. 2020, 9, 2620. [Google Scholar] [CrossRef] [PubMed]
- McCoy, S.S.; Woodham, M.; Bartels, C.M.; Saldanha, I.J.; Bunya, V.Y.; Maerz, N.; Akpek, E.K.; Makara, M.A.; Baer, A.N. Symptom-Based Cluster Analysis Categorizes Sjogren’s Disease Subtypes: An International Cohort Study Highlighting Disease Severity and Treatment Discordance. Arthritis Rheumatol. 2022, 74, 1569–1579. [Google Scholar] [CrossRef]
- Veenbergen, S.; Kozmar, A.; van Daele, P.L.A.; Schreurs, M.W.J. Autoantibodies in Sjogren’s syndrome and its classification criteria. J. Transl. Autoimmun. 2022, 5, 100138. [Google Scholar] [CrossRef]
- Garcia-Carrasco, M.; Ramos-Casals, M.; Rosas, J.; Pallares, L.; Calvo-Alen, J.; Cervera, R.; Font, J.; Ingelmo, M. Primary Sjogren syndrome: Clinical and immunologic disease patterns in a cohort of 400 patients. Medicine 2002, 81, 270–280. [Google Scholar] [CrossRef] [PubMed]
- Tan, E.M.; Feltkamp, T.E.; Smolen, J.S.; Butcher, B.; Dawkins, R.; Fritzler, M.J.; Gordon, T.; Hardin, J.A.; Kalden, J.R.; Lahita, R.G.; et al. Range of antinuclear antibodies in “healthy” individuals. Arthritis Rheum. 1997, 40, 1601–1611. [Google Scholar] [CrossRef] [PubMed]
- Fauchais, A.L.; Martel, C.; Gondran, G.; Lambert, M.; Launay, D.; Jauberteau, M.O.; Hachulla, E.; Vidal, E.; Hatron, P.Y. Immunological profile in primary Sjogren syndrome: Clinical significance, prognosis and long-term evolution to other auto-immune disease. Autoimmun. Rev. 2010, 9, 595–599. [Google Scholar] [CrossRef] [PubMed]
- Baer, A.N.; McAdams DeMarco, M.; Shiboski, S.C.; Lam, M.Y.; Challacombe, S.; Daniels, T.E.; Dong, Y.; Greenspan, J.S.; Kirkham, B.W.; Lanfranchi, H.E.; et al. The SSB-positive/SSA-negative antibody profile is not associated with key phenotypic features of Sjogren’s syndrome. Ann. Rheum. Dis. 2015, 74, 1557–1561. [Google Scholar] [CrossRef] [PubMed]
- Brito-Zeron, P.; Retamozo, S.; Ramos-Casals, M. Phenotyping Sjogren’s syndrome: Towards a personalised management of the disease. Clin. Exp. Rheumatol. 2018, 36 (Suppl. 112), 198–209. [Google Scholar]
- Min, H.K.; Kim, S.H.; Park, Y.; Lee, K.A.; Kwok, S.K.; Lee, S.H.; Kim, H.R. Ultrasonographic characteristics of major salivary glands in anti-centromere antibody-positive primary Sjogren’s syndrome. PLoS ONE 2021, 16, e0259519. [Google Scholar] [CrossRef]
- Jamilloux, Y.; Magy, L.; Hurtevent, J.F.; Gondran, G.; de Seze, J.; Launay, D.; Ly, K.H.; Lambert, M.; Hachulla, E.; Hatron, P.Y.; et al. Immunological profiles determine neurological involvement in Sjogren’s syndrome. Eur. J. Intern. Med. 2014, 25, 177–181. [Google Scholar] [CrossRef] [PubMed]
- Sene, D.; Jallouli, M.; Lefaucheur, J.P.; Saadoun, D.; Costedoat-Chalumeau, N.; Maisonobe, T.; Diemert, M.C.; Musset, L.; Haroche, J.; Piette, J.C.; et al. Peripheral neuropathies associated with primary Sjogren syndrome: Immunologic profiles of nonataxic sensory neuropathy and sensorimotor neuropathy. Medicine 2011, 90, 133–138. [Google Scholar] [CrossRef] [PubMed]
- Scofield, A.K.; Radfar, L.; Ice, J.A.; Vista, E.; Anaya, J.M.; Houston, G.; Lewis, D.; Stone, D.U.; Chodosh, J.; Hefner, K.; et al. Relation of sensory peripheral neuropathy in Sjogren syndrome to anti-Ro/SSA. J. Clin. Rheumatol. 2012, 18, 290–293. [Google Scholar] [CrossRef]
- Liampas, A.; Parperis, K.; Erotocritou, M.F.; Nteveros, A.; Papadopoulou, M.; Moschovos, C.; Akil, M.; Coaccioli, S.; Hadjigeorgiou, G.M.; Hadjivassiliou, M.; et al. Primary Sjogren syndrome-related peripheral neuropathy: A systematic review and meta-analysis. Eur. J. Neurol. 2023, 30, 255–265. [Google Scholar] [CrossRef]
pSS Cohort | ANA Negative | ANA (+) Non-Identified | ANA (+) Anti-Ro/SSA | ANA (+) Atypical | p-Value | ||
---|---|---|---|---|---|---|---|
(n = 233) | (n = 60) | (n = 42) | (n = 124) | (n = 7) | |||
DEMOGRAPHIC DATA | |||||||
Female | n (%) | 218 (93.6) | 55 (91.7) | 42 (100) | 114 (91.9) | 7 (100) | 0.233 |
Age at diagnosis | Med | 52 [17–85] | 58.5 [25–80] | 49.5 [28–85] | 48 [17–82] | 44 [23–69] | 0.0009 |
SICCA ASTHENIA POLYALGIA COMPLEX | |||||||
Fatigue | n (%) | 156/229 (68) | 31 (51.7) | 26 (61.9) | 96/120 (80) | 3 (42.9) | <0.0001 |
Chronic pain | n (%) | 171/232 (74) | 41 (68.3) | 31 (73.8) | 95/123 (77.2) | 4 (57.1) | 0.444 |
Dry eyes | n (%) | 212 (90.6) | 56 (93.3) | 41 (97.6) | 108 (87.1) | 6 (85.7) | 0.178 |
Xerostomia | n (%) | 210 (90.1) | 59 (98.3) | 40 (95.2) | 105 (84.7) | 6 (85.7) | 0.009 |
Positive Schirmer’s test | n (%) | 93/146 (63.7) | 25/40 (62.5) | 19/25 (76) | 46/76 (60.5) | 3/5 (60) | 0.568 |
Positive SG Scintigraphy | n (%) | 37/66 (56.1) | 4/10 (40) | 4/7 (57.1) | 29/47 (61.7) | 0/2 (0) | 0.240 |
SYSTEMIC MANIFESTATIONS | |||||||
Constitutional | n (%) | 5 (2.1) | 0 (0) | 1 (2.4) | 4 (3.2) | 0 (0) | _ |
Lymphadenopathy | n (%) | 8/231 (3.5) | 0 (0) | 0 (0) | 8/123 (6.5) | 0 (0) | _ |
Glandular | n (%) | 7 (3) | 0 (0) | 0 (0) | 7 (5.6) | 0 (0) | _ |
Articular | n (%) | 83 (35.6) | 9 (15) | 12 (28.6) | 60 (48.4) | 2 (28.6) | <0.0001 |
Cutaneous | n (%) | 11 (4.7) | 0 (0) | 0 (0) | 11 (8.9) | 0 (0) | _ |
Pulmonary | n (%) | 14/232 (6) | 0 (0) | 0 (0) | 14/123 (11.4) | 0 (0) | _ |
Renal | n (%) | 4 (1.7) | 0 (0) | 0 (0) | 4 (3.2) | 0 (0) | _ |
Muscular | n (%) | 1 (0.4) | 0 (0) | (0) | 1 (0.8) | 0 (0) | _ |
PNS | n (%) | 25/231 (10.8) | 11/59 (18.6) | 7/41 (17.1) | 4 (3.2) | 3 (42.9) | <0.0001 |
CNS | n (%) | 9 (3.9) | 4 (6.7) | 1 (2.4) | 4 (3.2) | 0 (0) | _ |
Hematological | n (%) | 3/232 (1.3) | 0 (0) | 0 (0) | 3 (2.4) | 0 (0) | _ |
Biological | n (%) | 76 (32.6) | 6 (10) | 4 (9.5) | 65 (52.4) | 1 (14.3) | <0.0001 |
ESSDAI at diagnosis | Med | 2 [0–23] | 0 [0–17] | 2 [0–10] | 3 [0–23] | 4 [0–15] | <0.0001 |
ESSDAI = 0 | n (%) | 80 (34.3) | 36 (60) | 19 (45.2) | 23 (18.5) | 2 (28.6) | <0.0001 |
ESSDAI < 5 | n (%) | 88 (37.8) | 11 (18.3) | 14 (33.3) | 61 (49.2) | 2 (28.6) | |
ESSDAI ≥ 5 | n (%) | 65 (27.9) | 13 (21.7) | 9 (21.4) | 40 (31.3) | 3 (42.9) | |
LABORATORY DATA | |||||||
Chisholm Score | |||||||
Chisholm 0 | n (%) | 14/209 (6.7) | 0 (0) | 0 (0) | 14/100 (14) | 0 (0) | _ |
Chisholm 1–2 | n (%) | 18/209 (8.6) | 0 (0) | 0 (0) | 18/100 (18) | 0 (0) | _ |
Chisholm 3–4 (FC ≥ 1) | n (%) | 177/209 (85) | 60 (100) | 42 (100) | 68/100 (68) | 7 (100) | _ |
ANA pattern | |||||||
Speckled | n (%) | 152 (65) | 0 (0) | 28 (66.7) | 121 (97.6) | 3 (42.9) | _ |
Homogeneous | n (%) | 26 (11.2) | 0 (0) | 18 (42.9) | 7 (5.6) | 1 (14.3) | _ |
Nucleolar | n (%) | 13 (5.6) | 0 (0) | 5 (11.9) | 8 (6.5) | 0 (0) | _ |
Others | n (%) | 8 (3.2) | 0 (0) | 2 (4.8) | 2 (1.6) | 4 (57.1) | _ |
ANA titer | |||||||
1:80 | n (%) | 51 (25.8) | 0 (0) | 17 (40.5) | 34 (27.4) | 0 (0) | _ |
1:160 | n (%) | 28 (12) | 0 (0) | 8 (19) | 20 (16.1) | 0 (0) | _ |
1:320 | n (%) | 20 (8.6) | 0 (0) | 7 (16.7) | 12 (9.2) | 1 (14.3) | _ |
1:640 | n (%) | 24 (10.3) | 0 (0) | 2 (4.8) | 21 (16.9) | 1 (14.3) | _ |
≥1:1280 | n (%) | 50 (21.4) | 0 (0) | 8 (19) | 37 (29.8) | 5 (71.4) | _ |
ANA identification | |||||||
Anti-Ro/SSA | n (%) | 124 (53.2) | 0 (0) | 0 (0) | 124 (100) | 0 (0) | _ |
Anti-La/SSB | n (%) | 52 (22.4) | 0 (0) | 0 (0) | 51 (41.1) | 1 (14.3) | _ |
Others ANA | n (%) | 15/227 (6.6) | 0 (0) | 0 (0) | 9/120 (7.5) | 6 (85.7) | _ |
Others immunological markers | |||||||
Cryoglobulinemia | n (%) | 16/138 (11.6) | 3/44 (6.8) | 3/31 (9.7) | 9/57 (15.8) | 1/6 (16.7) | 0.528 |
C4 consumption | n (%) | 11/161 (6.8) | 1/35 (2.9) | 0/28 (0) | 10/96 (10.4) | 0/2 (0) | 0.171 |
γ-globulins > 1600 g/dL | n (%) | 65/231 (28.1) | 3 (5) | 2 (4.5) | 59/122 (48.4) | 1 (14.3) | <0.0001 |
γ-globulins > 2000 g/dL | n (%) | 23/231 (10) | 1 (1.7) | 0 (0) | 22/122 (18) | 0 (0) | <0.0001 |
Rheumatoid Factor | n (%) | 63/200 (31.5) | 3/47 (6.4) | 7/39 (17.9) | 50/107 (46.7) | 3 (42.9) | <0.0001 |
THERAPEUTICS | |||||||
Hydroxychloroquine | n (%) | 122/231 (53) | 34/58 (58.6) | 27/42 (64.3) | 60 (48.4) | 1 (14.3) | 0.054 |
Immunosuppressant | n (%) | 26 (11.2) | 3 (5) | 1 (2.4) | 19 (15.3) | 3 (42.9) | 0.002 |
Methylprednisone PO | n (%) | 44/232 (19) | 1/59 (1.7) | 6/42 (14.3) | 33 (26.6) | 4 (57.1) | <0.0001 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Parisis, D.; Sarrand, J.; Cabrol, X.; Delporte, C.; Soyfoo, M.S. Clinical Profile of Patients with Primary Sjögren’s Syndrome with Non-Identified Antinuclear Autoantibodies. Diagnostics 2024, 14, 935. https://doi.org/10.3390/diagnostics14090935
Parisis D, Sarrand J, Cabrol X, Delporte C, Soyfoo MS. Clinical Profile of Patients with Primary Sjögren’s Syndrome with Non-Identified Antinuclear Autoantibodies. Diagnostics. 2024; 14(9):935. https://doi.org/10.3390/diagnostics14090935
Chicago/Turabian StyleParisis, Dorian, Julie Sarrand, Xavier Cabrol, Christine Delporte, and Muhammad S. Soyfoo. 2024. "Clinical Profile of Patients with Primary Sjögren’s Syndrome with Non-Identified Antinuclear Autoantibodies" Diagnostics 14, no. 9: 935. https://doi.org/10.3390/diagnostics14090935
APA StyleParisis, D., Sarrand, J., Cabrol, X., Delporte, C., & Soyfoo, M. S. (2024). Clinical Profile of Patients with Primary Sjögren’s Syndrome with Non-Identified Antinuclear Autoantibodies. Diagnostics, 14(9), 935. https://doi.org/10.3390/diagnostics14090935